

Sensitivity/specificity of commercial two tier testing for convalescent/late stage Lyme disease in the US*

Study/Year	Patients/Controls	Sensitivity	Specificity
Schmitz (1993)	25/28	66%	100%
Engstrom (1995)	55/159 [†]	55%	96%
Ledue (1996)	41/53	44%	100%
Tilton (1997)	23/23	45%	100%
Trevejo (1999)	74/38	29%	100%
Bacon (2003)	106/559	67%	99%
Binnicker (2008)	35/5	49%	100%
Steere (2008)	76/86 ^{††}	18%	99%
TOTAL	435/951	46%	99%
*Limited to studies from the US that included negative controls;			
[†] Non-commercial ELISA and Western blot; ^{††} Non-commercial ELISA			